Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 11:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–20 of 20 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Schizotypal Personality Disorder Clear all
Completed Not applicable Interventional

Feasibility Trial of a Lifestyle Intervention for CHR-P

NCT05532683
View directory record Official record
Conditions
Prodromal Schizophrenia, Psychosis, Psychological Disorder, Psychological Stress
Interventions
Health Behaviors Group
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
13 Years to 17 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 24, 2024 · Synced Jul 21, 2026, 11:36 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers

Pharmacology of Cognition in Schizotypal Personality Disorder

NCT00353379
View directory record Official record
Conditions
Schizotypal Personality Disorder, Personality Disorders
Interventions
Guanfacine, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 60 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1995 – 1997
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced Jul 21, 2026, 11:36 PM EDT
Active, not recruiting Not applicable Interventional

EPI-MINN: Targeting Cognition and Motivation - National

NCT05877716
View directory record Official record
Conditions
Psychosis, Psychosis Nos/Other, Schizophrenia, Schizo Affective Disorder, Schizoaffective Disorder, Prodromal Schizophrenia, Schizophrenia Spectrum and Other Psychotic Disorders, Schizophreniform Disorders, Major Depression With Psychotic Features, Unspecified Psychosis, Bipolar Disorder
Interventions
Cognitive and Social Cognitive Training, Personalized Real-Time Intervention for Motivational Enhancement (PRIME) App, Early Psychosis Coordinated Specialty Care
Device · Behavioral · Other
Lead sponsor
University of Minnesota
Other
Eligibility
15 Years to 40 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Jul 21, 2026, 11:36 PM EDT
Completed No phase listed Observational Results available

Second-Generation Antipsychotic Treatment Indication Effectiveness And Tolerability In Youth (Satiety) Study

NCT01269710
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychotic Disorder, Not Otherwise Specified, Prodromal Schizophrenia, Mood Disorder, Bipolar Disorder, Major Depressive Disorder, Depressive Disorder, Not Otherwise Specified, Mood Disorder, Not Otherwise Specified, Autism Spectrum Disorder
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
3 Years to 19 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 21, 2013 · Synced Jul 21, 2026, 11:36 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

CRT-Guanfacine for SPD

NCT02524899
View directory record Official record
Conditions
Schizotypal Personality Disorder, SPD
Interventions
Cognitive Remediation Therapy, Guanfacine, Placebo
Behavioral · Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Jul 21, 2026, 11:36 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Randomized Clinical Trial of Intensive Computer-based Cognitive Remediation in Recent-onset Schizophrenia

NCT01773239
View directory record Official record
Conditions
Schizophrenia
Interventions
TARA computer-based exercises
Behavioral
Lead sponsor
Posit Science Corporation
Industry
Eligibility
18 Years to 35 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 29, 2016 · Synced Jul 21, 2026, 11:36 PM EDT
Not listed Phase 2 Interventional

Clinical Testing of a D1 Agonist for Cognitive Enhancement in Schizotypal Personality Disorder

NCT01466205
View directory record Official record
Conditions
Cognitive Impairments, Schizotypal Personality Disorder
Interventions
DAR-0100A, Placebo
Drug
Lead sponsor
Larry J. Siever
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 19, 2012 · Synced Jul 21, 2026, 11:36 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A D1 Agonist For Working Memory

NCT02507206
View directory record Official record
Conditions
Schizotypal Personality Disorder, SPD
Interventions
DAR 0-100A, Placebo
Drug
Lead sponsor
Antonia New
Other
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 8, 2018 · Synced Jul 21, 2026, 11:36 PM EDT
Enrolling by invitation No phase listed Observational

Evaluation of Step-Based Care for Individuals at Clinical High Risk for Psychosis

NCT03970005
View directory record Official record
Conditions
Prodromal Schizophrenia
Interventions
Step-Based Care Model
Behavioral
Lead sponsor
Ohio State University
Other
Eligibility
12 Years to 25 Years
Enrollment
100 participants
Timeline
2019 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Jul 21, 2026, 11:36 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Examining Dose-Related Effects of Oxytocin on Social Cognition Across Populations

NCT02149823
View directory record Official record
Conditions
Borderline Personality Disorder, BPD, Schizotypal Personality Disorder, SPD, Autism Spectrum Disorder, Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
Interventions
Syntocinon 24 Intranasal Units (IU), Syntocinon 40 Intranasal Units (IU), Intranasal Placebo
Drug
Lead sponsor
Maria de las Mercedes Perez Rodriguez
Other
Eligibility
18 Years to 65 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2022
U.S. locations
2
States / cities
New York, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 9, 2022 · Synced Jul 21, 2026, 11:36 PM EDT
Completed Not applicable Interventional

Neurofeedback Training for High Risk Psychosis

NCT03447548
View directory record Official record
Conditions
Prodromal Schizophrenia
Interventions
Neurofeedback processing speed training, Active control
Behavioral
Lead sponsor
Hartford Hospital
Other
Eligibility
12 Years to 25 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 27, 2024 · Synced Jul 21, 2026, 11:36 PM EDT
Not listed Not applicable Interventional

Pergolide for Cognitive Symptoms in Schizotypal Personality Disorder

NCT00252044
View directory record Official record
Conditions
Schizotypal Personality Disorder, Other Personality Disorders
Interventions
Pergolide
Drug
Lead sponsor
Bronx VA Medical Center
Federal
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 20, 2005 · Synced Jul 21, 2026, 11:36 PM EDT
Active, not recruiting Not applicable Interventional

Family-Focused Therapy for Individuals at High Clinical Risk for Psychosis: A Confirmatory Efficacy Trial

NCT04338152
View directory record Official record
Conditions
Psychotic Disorders, Prodromal Symptoms, Prodromal Schizophrenia, Psychosis, Family
Interventions
Family Focused Therapy for Clinical High Risk Youth (FFT-CHR), Enhanced Care (EC)
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
13 Years to 25 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
6
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2026 · Synced Jul 21, 2026, 11:36 PM EDT
Completed Not applicable Interventional

Risperidone in the Treatment of Psychotic-like and Deficit Symptoms of Schizotypal Personality Disorder

NCT00158028
View directory record Official record
Conditions
Schizotypal Personality Disorder
Interventions
Risperidone, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2001
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 3, 2016 · Synced Jul 21, 2026, 11:36 PM EDT
Terminated Not applicable Interventional

Aripiprazole Treatment of the Prodrome

NCT00169949
View directory record Official record
Conditions
Prodromal Schizophrenia, Prodromal Psychosis
Interventions
aripiprazole
Drug
Lead sponsor
Northwell Health
Other
Eligibility
13 Years to 22 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Sep 24, 2009 · Synced Jul 21, 2026, 11:36 PM EDT
Recruiting Not applicable Interventional

Targeting Processing Speed Deficits to Improve Social Functioning and Lower Psychosis Risk

NCT05131035
View directory record Official record
Conditions
Psychosis, Prodromal Schizophrenia, Prodromal Symptoms
Interventions
SCORES (Specific COgnitive Remediation with Support)
Behavioral
Lead sponsor
Northwell Health
Other
Eligibility
14 Years to 20 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Nov 23, 2025 · Synced Jul 21, 2026, 11:36 PM EDT
Suspended Phase 1Phase 2 Interventional

Accelerated TMS in Psychosis

NCT05567848
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Prodromal Schizophrenia
Interventions
repetitive Transcranial Magnetic Stimulation (rTMS)
Device
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Jul 21, 2026, 11:36 PM EDT
Not yet recruiting Not applicable Interventional

Online Intervention To Improve Motivation

NCT07157293
View directory record Official record
Conditions
Schizophrenia Prodromal, SCHIZOPHRENIA 1 (Disorder), Psychosis
Interventions
Online Motivation Enhancing Intervention
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Jul 21, 2026, 11:36 PM EDT
Completed Not applicable Interventional

Antidepressant and Antipsychotic to Treat Attenuated Positive and Negative Symptoms

NCT00169988
View directory record Official record
Conditions
Prodromal Schizophrenia, Psychotic Disorders
Interventions
risperidone, sertraline-primary
Drug
Lead sponsor
Northwell Health
Other
Eligibility
12 Years to 22 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Dec 16, 2009 · Synced Jul 21, 2026, 11:36 PM EDT
Completed Not applicable Interventional Results available

Psychosis: Early Detection, Intervention and Prevention

NCT01597141
View directory record Official record
Conditions
Prodromal Schizophrenia, Psychotic Disorders, Severe Bipolar Disorder With Psychotic Features, Severe Major Depression With Psychotic Features
Interventions
Family-aided Assertive Community Treatment, Enhanced standard treatment
Behavioral
Lead sponsor
MaineHealth
Other
Eligibility
12 Years to 35 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2014
U.S. locations
1
States / cities
Portland, Maine
Source: ClinicalTrials.gov public record
Updated Feb 7, 2016 · Synced Jul 21, 2026, 11:36 PM EDT